Podrobno

Pokojninsko zavarovanje : diplomsko delo univerzitetnega programa
ID Sinjur, Urška (Avtor), ID Pevcin, Primož (Mentor) Več o mentorju... Povezava se odpre v novem oknu

.pdfPDF - Predstavitvena datoteka, prenos (1,08 MB)
MD5: 7554F32E835BF79E1306C3236374CD25
PID: 20.500.12556/rul/673d1a15-866e-4f74-9bcc-22a39e595669

Jezik:Slovenski jezik
Ključne besede:pokojnine, pokojninski skladi, pokojninsko zavarovanje, Slovenija, diplomske naloge
Vrsta gradiva:Diplomsko delo
Tipologija:2.11 - Diplomsko delo
Organizacija:FU - Fakulteta za upravo
Kraj izida:Ljubljana
Založnik:[U. Sinjur]
Leto izida:2009
Št. strani:IV, 58 str.
PID:20.500.12556/RUL-2459 Povezava se odpre v novem oknu
UDK:368.914(497.4)(043.2)
COBISS.SI-ID:3267246 Povezava se odpre v novem oknu
Datum objave v RUL:11.07.2014
Število ogledov:4215
Število prenosov:533
Metapodatki:XML DC-XML DC-RDF
:
SINJUR, Urška, 2009, Pokojninsko zavarovanje : diplomsko delo univerzitetnega programa [na spletu]. Diplomsko delo. Ljubljana : U. Sinjur. [Dostopano 25 marec 2025]. Pridobljeno s: https://repozitorij.uni-lj.si/IzpisGradiva.php?lang=slv&id=2459
Kopiraj citat
Objavi na:Bookmark and Share

Podobna dela

Podobna dela v RUL:
  1. ǂThe ǂimportance of cancer stem cells and epithelial-mesenchymal transition in the progression of non-small cell lung cancer
  2. Gene expression levels of the prolyl hydroxylase domain proteins PHD1 and PHD2 but not PHD3 are decreased in primary tumours and correlate with poor prognosis of patients with surgically resected non-small-cell lung cancer
  3. Study of phosphatidylethanolamine N-methyltransferase gene expression in non-small cell lung cancer tissue
  4. Usefulness of immunohistochemically determined epidermal growth factor receptor mutations in lung cancer
  5. Diabetes mellitus and physical activity
Podobna dela v drugih slovenskih zbirkah:
  1. Expression patterns and prognostic relevance of subtype-specific transcription factors in surgically resected small cell lung cancer
  2. Outsourcing predictive biomarker testing in non-small cell carcinoma
  3. Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer
  4. Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer
  5. NSCLC molecular testing in Central and Eastern European countries

Nazaj